ArticleHemodialysis international. International Symposium on Home Hemodialysis2020
Safety and efficacy of the Tablo hemodialysis system for in-center and home hemodialysis.
Article in Hemodialysis international. International Symposium on Home Hemodialysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Home versus in-centre haemodialysis for people with kidney failure.The Cochrane database of systematic reviews · 2024Pooled it
- A Novel Substrate-Inspired Fluorescence-Based Albumin Detection Improves Assessment of Clinical Outcomes in Hemodialysis Patients Receiving a Nursing Nutrition Intervention.Medical science monitor : international medical journal of experimental and clinical research · 2021Trial
- A Prospective, Multicenter, Open-Label Assessment of Efficacy and Safety of the Quanta Dialysis System for Home Hemodialysis.Kidney medicine · 2026Article
- Vascular Access for Home Hemodialysis: A Perspective on Tunneled Central Venous Catheters at Home.Kidney medicine · 2025Review
- The impact of dialysate flow rate on haemodialysis adequacy: a systematic review and meta-analysis.Clinical kidney journal · 2024Article
- The use of Tablo continuous veno-venous haemodialysis to rapidly remove lithium in a patient with severe lithium toxicity.BMJ case reports · 2023Article
- Two Years' Experience of Intensive Home Hemodialysis with the Physidia SJournal of clinical medicine · 2023Article
- Funding Innovative Dialysis Technology in the United States: Home Dialysis and the ESRD Transitional Add-on Payment for New and Innovative Equipment and Supplies (TPNIES).American journal of kidney diseases : the official journal of the National Kidney Foundation · 2021Article
- Self-care training using the Tablo hemodialysis system.Hemodialysis international. International Symposium on Home Hemodialysis · 2021Article
- Patient-reported outcomes from the investigational device exemption study of the Tablo hemodialysis system.Hemodialysis international. International Symposium on Home Hemodialysis · 2020Article
- Technology, Telehealth, and Nephrology: The Time Is Now.Kidney360 · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHome hemodialysis remains underutilized despite observational data indicating more favorable outcomes with home compared with in-center hemodialysis. The Tablo Hemodialysis system is designed to be easy to learn and use and to facilitate adoption of home hemodialysis. The objective of the current investigational device exemption (IDE) study was to evaluate the safety and efficacy of Tablo managed in-center by health care professionals and in-home by patients and/or caregivers.
methodsA prospective, multicenter, open-label, crossover trial comparing in-center and in-home hemodialysis using Tablo. There were 4 treatment periods during which hemodialysis was prescribed 4 times per week: 1-week Run-In, 8-week In-Center, 4-week Transition, and 8-week In-Home. The primary efficacy endpoint was weekly standard Kt/V
findingsThirty participants enrolled and 28 completed all trial periods. Adherence to the protocol requirement of 4 treatments per week was 96% in-center and 99% in-home. The average prescribed and delivered session lengths were 3.4 hours for both the In-Center and the In-Home periods. The primary efficacy endpoint for the intention-to-treat cohort was achieved in 199/200 (99.5%) of measurements during the In-Center period and 168/171 (98.3%) In-Home. The average weekly standard Kt/V
conclusionPrimary and secondary efficacy and safety endpoints were achieved during both In-Center and In-Home trial periods. This study confirms that Tablo is safe and effective for home hemodialysis use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.